Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Puerto Rican competitiveness is key to Puerto Rican pharma R&D.

Juma’h et al. 15 [ Ahmad H. Juma’h , Ph.D., C.P.A., Ph.D. in Accounting and Finance from Manchester Business School; Doris Morales-Rodríguez , Ph.D., doctorate in Entrepreneurial and Management Development in International Business from Inter American University of Puerto Rico, Metropolitan Campus.; Antonio Lloréns-Rivera , Ph.D. in Public Policy and Management with majors in Public Finance and Urban Economics from The Ohio State University; “Pharmaceutical Industry and R&D in Puerto Rico”; Labor Markets and Multinational Enterprises in Puerto Rico; 2015; https://link.springer.com/chapter/10.1007/978-3-319-17178-4_6]//eleanor

It is noted that the efforts of the Government of Puerto Rico to strengthen value- added activities in the biotechnology sector is one devoid of guarantees for the pharmaceutical long term activity on the Island due to an erosion of the global market. It argues that the Island faces the threat of development and manufacturing of medicines in low-cost jurisdictions such as India and China. It also faces the loss of competitiveness in the R&D sector in countries like Ireland and Singapore. Furthermore, changes in tax incentives at the local level have also weakened the mood of industry for economic activity in Puerto Rico. Considering adverse aspects, the fi nancial crisis of local government is also added. This situation is added to other events such as the maturity of the exemptions provided by Section 936 in 2006 and the increasing of labor costs (Business Monitor International 2006 ; Morales et al. 2012 ).

As presented by the Pharmaceutical Industry Executives some of the considerations for establishing both pharmaceutical operations and R&D include the following factors: the transaction costs, the economy, infrastructure, human resource, quality of life, technology, enabling environment for trade, education, cost of living and access to capital (PIE 2013 ). When analyzing the economic indicators of the countries with high establishment of the pharmaceutical R&D, these countries offer incentives and have a number of economic advantages over Puerto Rico; they have competitive advantages to multinationals for R&D center establishment. The economic indicators show how these countries are developing positively, with low unemployment rates and positive growth of GDP. Similarly, educational indicators can be used as a measure or important for the establishment of R&D centers factor. Higher education plays a key role in innovation, important part of R&D. Also, the location of the best universities in the world matches the host countries of R&D centers.

Puerto Rico despite having a pharmaceutical presence of many years in as manufacturing operations has not been fully developed in R&D. In Puerto Rico, basic research that do not generate patents are held. However, currently only has a limited amount of R&D centers, 12 in total (see Fig. 6.2 ). Of these, seven centers were established as a result of R&D incentives granted by Law 73 of 2008 (i.e. Law on Economic Incentives for Economic Development of Puerto Rico).

Also, some universities have limited investment in R&D funds. In addition, several companies are developing biotechnology activities on the Island (see Table 6.3 ). However, the lack of data on economic indicators and the R&D activities on the Puerto Rico do not help to promote the importance of R&D in the economy.

To compete in the new global economy and to compete with countries like Singapore, Malaysia, Ireland, Finland, India and Indonesia, it is recommended to direct efforts to promote and develop a knowledge-based economy. Puerto Rico has begun to develop initiatives in the development of knowledge. As part of the efforts that have been developed are partnerships with universities, academic programs in biotechnology and the collection of data on R&D in Puerto Rico by the Statistical Offi ce of Puerto Rico.

The partnership between the University of Puerto Rico and the MD Anderson Cancer Center (located in Texas and known for its comprehensive center dedicated exclusively to the treatment, research, education and prevention of cancer), for purposes of research and treatment of the Hispanic population is such example. Puerto Rico participation in R&D is limited and disadvantage over other competitors, yet efforts increase. It is starting to generate an infrastructure aimed at the knowledge economy and is expected to innovation activity in the Island increase in the years to come (see Fig. 6.3 ).

The pharmaceutical industry in Puerto Rico is an important and integral part of the economy and if a signifi cant reduction of it is occurred, the results would be unfavorable for the whole economy of Puerto Rico. Among the negative effects are the unemployment rate would rise and GDP is signifi cantly reduced. The competitiveness of Puerto Rico is declining. Possible factors for the loss of competitiveness include the political uncertainty in Puerto Rico, high energy costs and lack of partners in scientifi c research. These factors lead to a diffi cult Puerto Rico when attracting new projects for the manufacture of products (Guillen 2009 ) situation.

The Island still has the presence in pharmaceutical manufacturing of the best in the world and produces a large amount of drugs with overall higher market sales. Moreover, in recent years have prompted efforts to maintain the presence of existing companies and develop new areas such as biotechnology and R&D. But Puerto Rico is not the only country to develop these efforts. Countries like Taiwan, Malaysia and Singapore have aimed their efforts to develop biotechnology. Aspects such as a strategic location to develop pharmaceutical and biotechnology industries contribute to the positioning of competing countries like Ireland and Singapore. Also, the economic incentives that these two countries offer may be similar to those of Puerto Rico.

Despite the disrupted of Section 936, Puerto Rico still has a skilled workforce, a work tradition focused on quality, infrastructure facilities and high-level communication. Industry executives indicated that they still observe a level of competitiveness that can be aimed to the development of specifi c sectors in the industry, so the refocus of the pharmaceutical industry in Puerto Rico is proposed, one directed to the manufacture of generic drugs.

The generics market represents an area of growth and opportunity for Puerto Rico. Generic drugs accounted for 80 % of the global market for 2012, and it is projected to continue to grow (see Fig. 6.4 ). It is noted that the Island still has some strengths that contribute signifi cantly to competitiveness and make it attractive to develop a generic industry (PIE 2013 ). These strengths are listed as: high technical knowledge, acuity and managerial experience, plants (infrastructure) available, diversity of human resources, lots of universities and technical colleges, some centers of R&D existing infrastructure for water, electricity and communications, location and logistics system, and the new Investment Act (PIE 2013 ). Furthermore, a high expertise arises in the process of quality control that leads to Puerto Rico in compliance with FDA regulations over other competing countries, especially India and China face.

On other hand, some weakness are identifi ed that include poor education of English language and mathematics, poor entrepreneurship, defi ciencies in the use of tools and improvement processes, the lack of a development of long term plan and agility to issued licenses and permits (PIE 2013 ). But business groups in the pharmaceutical industry; betting convert Puerto Rico in generic drugs manufacturing center.

Conclusions

Puerto Rico faces the decline of the manufacturing sector and its main industry branch, the pharmaceutical industry. The loss of competitiveness and macroeconomic factors contribute to this situation. This raises the need for assertive strategies to address the negative implications for the economy, such as reducing jobs and GDP.

It is necessary not only to establish strategies for the retention of established pharmaceutical plants, but also completely re-focus the development strategy and industrial promotion. Apparently the address could be more feasible in this new strategy is based on developing a generic manufacturing, in which the business Fig. 6.4 Market growth of generics. Source : IMS Health, National Sales Perspectives, June 2012, National Prescription Audit, June 2012, disaggregated Branded generics. Presented by the PIE at the Annual Meeting of the Puerto Rico Economists Association on August 30, 2013 community itself has identifi ed some competitive advantages for Puerto Rico compared to those competitors and emerging countries, particularly Ireland, Singapore and Malaysia.

It is also important to increase the activity of R&D on the Island. Although formulated initiatives in order to promote the establishment of centers of R&D and the creation of new knowledge, they may not be enough, so it is necessary to evaluate and redirect these measures.

Sign in to recut, update, or save this card.